Published Sep 8, 2026
Erasca (ERAS): A RAS Franchise Rebuilt Around Two Clinical Molecules
In-depth research on ERAS covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,394 words15 min read
Read report